FAP and non-small cell lung carcinoma: We showed that C3F could be detected in serum and saw elevated levels of C3F for both patients with NSCLC and SpA compared to healthy subjects, thus demonstrating a novel association between serum levels of C3F and the two diseases, indicating a diagnostic biomarker potential of C3F for FAP-related diseases.